share_log

Goldman Sachs Reinstates Neutral on Altimmune, Announces $13 Price Target

Benzinga ·  Jan 24 20:04

Goldman Sachs analyst Corinne Jenkins reinstates Altimmune (NASDAQ:ALT) with a Neutral and announces $13 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment